Ophthalmology Focus Kriya’s geographic atrophy focused ophthalmology programs and exclusive Everads collaboration signal strong demand for ophthalmology‑specific development services, manufacturing support, and regulatory guidance; ideal for targeted CRO/CDMO partners and vector supply vendors.

One-time Therapy The push to develop a one‑time gene therapy that blocks complement C3 and C5 creates opportunities for joint development, long‑term efficacy planning, and scalable manufacturing partnerships.

Strategic Partnerships A diverse pipeline across ophthalmology, metabolic disease and neurology opens multiple licensing or co‑development opportunities with large pharma seeking gene therapy assets.

Global Footprint Operations in North Carolina and California place Kriya within major biotech hubs, enabling access to regional clinical sites, talent, and potential global trial and manufacturing collaborations.

Financial Readiness Visible funding and revenue presence support upfront and milestone‑based deal structures, making Kriya an appealing partner for collaborations aimed at rapid clinical translation to commercialization.